VEGFA and cancer: Sorafenib, a novel molecular targeted therapeutic agent, can block the signal pathway of receptor tyrosine kinase, reduce VEGF activity in the hepatic artery, slow down the neoangiogenesis for oxygen and blood supply, and thus inhibit cancer cell metastasis [20, 21], so the treated VEGF level of patients in group A who received both treatment modalities was significantly lower than that in group B (p < 0.001), indicating a reduced migration rate of the cancer tissue.